Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia in Chinese Patients

NCT05410860 is registered in ClinicalTrials.gov with Corxel Pharmaceuticals as lead sponsor.

NCT NCT05410860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05410860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia in Chinese Patients
Lead sponsor
Corxel Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2022
Completion date
December 10, 2024
Enrollment
500 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal supraventricular tachycardia, tachycardia, supraventricular